短期致幻剂和人工智能驱动的行为监测的精神病治疗。

IF 3.5 3区医学 Q2 CHEMISTRY, MEDICINAL

ACS Medicinal Chemistry Letters Pub Date : 2025-01-29 eCollection Date: 2025-02-13 DOI:10.1021/acsmedchemlett.5c00031

Robert B Kargbo

{"title":"短期致幻剂和人工智能驱动的行为监测的精神病治疗。","authors":"Robert B Kargbo","doi":"10.1021/acsmedchemlett.5c00031","DOIUrl":null,"url":null,"abstract":"Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors (SSRIs) with short-acting psychedelics, such as N,N-dimethyltryptamine (DMT) and psilocybin, provides rapid and sustained improvements in treatment-resistant depression and anxiety. Meanwhile, AI-enhanced behavioral monitoring leverages motion tracking and machine learning to quantify treatment outcomes in animal models, accelerating drug development. Together, these approaches redefine therapeutic paradigms, offering personalized and effective treatments for psychiatric disorders.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"219-221"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831372/pdf/","citationCount":"0","resultStr":"{\"title\":\"Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.\",\"authors\":\"Robert B Kargbo\",\"doi\":\"10.1021/acsmedchemlett.5c00031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors (SSRIs) with short-acting psychedelics, such as N,N-dimethyltryptamine (DMT) and psilocybin, provides rapid and sustained improvements in treatment-resistant depression and anxiety. Meanwhile, AI-enhanced behavioral monitoring leverages motion tracking and machine learning to quantify treatment outcomes in animal models, accelerating drug development. Together, these approaches redefine therapeutic paradigms, offering personalized and effective treatments for psychiatric disorders.\",\"PeriodicalId\":20,\"journal\":{\"name\":\"ACS Medicinal Chemistry Letters\",\"volume\":\"16 2\",\"pages\":\"219-221\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831372/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acsmedchemlett.5c00031\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/13 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsmedchemlett.5c00031","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/13 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

整合先进的药物创新和人工智能（AI）为精神病学护理提供了变革性的潜力。本专利重点回顾了新的治疗策略，包括单胺类抗抑郁药和短效致幻剂的协同使用，以及人工智能驱动的行为疗效跟踪。选择性5 -羟色胺再摄取抑制剂（SSRIs）与短效致幻剂（如N，N-二甲基色胺（DMT）和裸盖菇素）联合使用，可快速持续地改善难治性抑郁和焦虑。与此同时，人工智能增强的行为监测利用运动跟踪和机器学习来量化动物模型的治疗结果，从而加速药物开发。总之，这些方法重新定义了治疗范式，为精神疾病提供了个性化和有效的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.

Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors (SSRIs) with short-acting psychedelics, such as N,N-dimethyltryptamine (DMT) and psilocybin, provides rapid and sustained improvements in treatment-resistant depression and anxiety. Meanwhile, AI-enhanced behavioral monitoring leverages motion tracking and machine learning to quantify treatment outcomes in animal models, accelerating drug development. Together, these approaches redefine therapeutic paradigms, offering personalized and effective treatments for psychiatric disorders.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Medicinal Chemistry Letters CHEMISTRY, MEDICINAL-

CiteScore

7.30

自引率

2.40%

发文量

328

审稿时长

1 months

期刊介绍： ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to: Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics) Biological characterization of new molecular entities in the context of drug discovery Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc. Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic Mechanistic drug metabolism and regulation of metabolic enzyme gene expression Chemistry patents relevant to the medicinal chemistry field.